Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by OpGen, Inc.
OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
April 23, 2024
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Announces Acquisition of Preferred Stock by David Lazar
March 25, 2024
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
October 12, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
August 07, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
August 03, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
June 20, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Announces Closing of $3.5 Million Public Offering
May 04, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Announces Pricing of $3.5 Million Public Offering
May 01, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
April 26, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
April 18, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
April 18, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
April 05, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
April 03, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
March 22, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
March 01, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Announces Exercise of All Prefunded Warrants
February 17, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen subsidiary Ares Genetics announces granting of key patent in China
January 26, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
January 18, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
January 17, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
OpGen Announces Closing of $7.5 Million Public Offering
January 11, 2023
From
OpGen, Inc.
Via
GlobeNewswire
Tickers
OPGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.